X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will support the accelerated development of ZB-106 (tibulizumab), including the planned Phase 2 clinical trial in systemic sclerosis (SSc), the initiation of a Phase 2 trial evaluating tibulizumab for the treatment of hidradenitis suppurativa.
Lead Product(s): Tibulizumab
Therapeutic Area: Immunology Product Name: ZB-106
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Access Biotechnology
Deal Size: $112.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 18, 2024
Details:
The funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 (tibulizumab), a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist, in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).
Lead Product(s): Tibulizumab
Therapeutic Area: Immunology Product Name: ZB-106
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 06, 2023
Details:
Through the agreement, Zura Bio will expand its Immunology pipeline by including ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist.
Lead Product(s): Tibulizumab
Therapeutic Area: Immunology Product Name: ZB-106
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Eli Lilly
Deal Size: Undisclosed Upfront Cash: $4.2 million
Deal Type: Licensing Agreement April 27, 2023
Details:
The net proceedings will be used to to initiate a Phase 2 study for ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist, in Systemic Sclerosis.
Lead Product(s): Tibulizumab
Therapeutic Area: Immunology Product Name: ZB-106
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $80.0 million Upfront Cash: $80.0 million
Deal Type: Private Placement April 27, 2023
Details:
The combined company will focus on the clinical development of pipeline candidates ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways.
Lead Product(s): ZB-168
Therapeutic Area: Endocrinology Product Name: ZB-168
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: JATT Acquisition
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2023
Details:
Proceeds from the transaction are expected to provide Zura Bio with the capital needed to accelerate the development of ZB-168, a fully-human, clinical-stage antibody targeting IL7Rα, that was recently in-licensed from Pfizer Inc.
Lead Product(s): ZB-168
Therapeutic Area: Endocrinology Product Name: ZB-168
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: JATT Acquisition Corp
Deal Size: Undisclosed Upfront Cash: $65.0 million
Deal Type: Merger June 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
